Olivier Brandicourt, M.D., joined our Board of Directors in January 2024.

Dr. Brandicourt has decades of management, medical and marketing experience in the global pharmaceutical industry, including as a senior leader of three global pharmaceutical companies. From 2015 to 2019, Dr. Brandicourt served as Chief Executive Officer and as a member of the board of directors of Sanofi S.A. Prior to Sanofi, he was the Chief Executive Officer and Chair of Bayer HealthCare AG from 2013 to 2015. From 2000 to 2013, Dr. Brandicourt served in various operational and managerial positions at Pfizer Inc., including as a member of the Executive Leadership Team and President and General Manager of the Emerging Markets and Established Products business units, amongst other roles. Dr. Brandicourt is currently a Senior Advisor at Blackstone Life Sciences, and serves as a board director of Alnylam Pharmaceuticals, AvenCell Therapeutics (Chair), BenevolentAI S.A., and Dewpoint Therapeutics.

Dr. Brandicourt studied medicine in Paris where he specialized in Infectious Diseases and Tropical Medicine and holds a Master’s Degree in Biology and an Advanced Degree in Cellular and Immunological Pathophysiology. He is an Honorary Fellow of the Royal College of Physicians in London.